JP5301990B2 - 細胞の培養寿命の延長および培養細胞からのタンパク質収量を増加させるための改良された方法および組成物 - Google Patents

細胞の培養寿命の延長および培養細胞からのタンパク質収量を増加させるための改良された方法および組成物 Download PDF

Info

Publication number
JP5301990B2
JP5301990B2 JP2008523951A JP2008523951A JP5301990B2 JP 5301990 B2 JP5301990 B2 JP 5301990B2 JP 2008523951 A JP2008523951 A JP 2008523951A JP 2008523951 A JP2008523951 A JP 2008523951A JP 5301990 B2 JP5301990 B2 JP 5301990B2
Authority
JP
Japan
Prior art keywords
cells
cell
bcl
antibody
cell line
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2008523951A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009502167A5 (OSRAM
JP2009502167A (ja
Inventor
ゴールデンバーグ，デイヴィッド・エム
クー，チェンシン
チャン，チエン・シン
ロッシ，エドワード・エイ
ヤン，ジェン‐ダー
ノードストローム，ダイアン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Immunomedics Inc
Original Assignee
Immunomedics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunomedics Inc filed Critical Immunomedics Inc
Publication of JP2009502167A publication Critical patent/JP2009502167A/ja
Publication of JP2009502167A5 publication Critical patent/JP2009502167A5/ja
Application granted granted Critical
Publication of JP5301990B2 publication Critical patent/JP5301990B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4747—Apoptosis related proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3007—Carcino-embryonic Antigens
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0693—Tumour cells; Cancer cells
    • C12N5/0694—Cells of blood, e.g. leukemia cells, myeloma cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/90—Serum-free medium, which may still contain naturally-sourced components
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/40—Regulators of development
    • C12N2501/48—Regulators of apoptosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
JP2008523951A 2005-07-25 2006-07-14 細胞の培養寿命の延長および培養細胞からのタンパク質収量を増加させるための改良された方法および組成物 Active JP5301990B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11/187,863 2005-07-25
US11/187,863 US7531327B2 (en) 2004-07-23 2005-07-25 Methods and compositions for increasing longevity and protein yield from a cell culture
PCT/US2006/027820 WO2007015848A2 (en) 2005-07-25 2006-07-14 Improved methods and compositions for increasing longevity and protein yield from a cell culture

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2013084178A Division JP2013172722A (ja) 2005-07-25 2013-04-12 細胞の培養寿命の延長および培養細胞からのタンパク質収量を増加させるための改良された方法および組成物

Publications (3)

Publication Number Publication Date
JP2009502167A JP2009502167A (ja) 2009-01-29
JP2009502167A5 JP2009502167A5 (OSRAM) 2009-08-27
JP5301990B2 true JP5301990B2 (ja) 2013-09-25

Family

ID=37709058

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2008523951A Active JP5301990B2 (ja) 2005-07-25 2006-07-14 細胞の培養寿命の延長および培養細胞からのタンパク質収量を増加させるための改良された方法および組成物
JP2013084178A Pending JP2013172722A (ja) 2005-07-25 2013-04-12 細胞の培養寿命の延長および培養細胞からのタンパク質収量を増加させるための改良された方法および組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2013084178A Pending JP2013172722A (ja) 2005-07-25 2013-04-12 細胞の培養寿命の延長および培養細胞からのタンパク質収量を増加させるための改良された方法および組成物

Country Status (8)

Country Link
US (1) US7531327B2 (OSRAM)
EP (1) EP1910515B1 (OSRAM)
JP (2) JP5301990B2 (OSRAM)
KR (2) KR101518062B1 (OSRAM)
CN (1) CN101273121B (OSRAM)
AU (1) AU2006276182B2 (OSRAM)
CA (1) CA2616799C (OSRAM)
WO (1) WO2007015848A2 (OSRAM)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7537930B2 (en) 2004-07-23 2009-05-26 Immunomedics, Inc. Mammalian cell lines for increasing longevity and protein yield from a cell culture
US7531327B2 (en) 2004-07-23 2009-05-12 Immunomedics, Inc. Methods and compositions for increasing longevity and protein yield from a cell culture
US7608425B2 (en) * 2004-07-23 2009-10-27 Immunomedics, Inc. Methods for protein expression in mammalian cells in serum-free medium
US20070092947A1 (en) * 2005-10-20 2007-04-26 Immunomedics, Inc. Methods and compositions for increasing longevity and protein yield from a cell culture
KR101802393B1 (ko) * 2008-06-10 2017-11-28 상가모 테라퓨틱스, 인코포레이티드 Ｂａｘ- 및 ｂａｋ-결함 세포주들의 제조 방법 및 조성물
WO2009152413A1 (en) * 2008-06-13 2009-12-17 Centocor Ortho Biotech Inc. Methods for obtaining high viable cell density in mammalian cell culture
DE102008051574A1 (de) * 2008-10-14 2010-04-15 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Verfahren zur Herstellung von Interferon-beta und deren Varianten
CN102369276B (zh) 2009-02-20 2015-02-04 文特里亚生物科学公司 含有蛋白质组合的细胞培养基
CN101899471B (zh) * 2009-05-26 2014-06-11 中国医学科学院基础医学研究所 同时表达抗原特异性受体和外源基因的重组逆转录病毒载体、用其修饰的b-淋巴细胞及其用途
CN102482701B (zh) 2009-09-16 2015-05-13 免疫医疗公司 I类抗-cea抗体及其使用
WO2011068845A1 (en) 2009-12-02 2011-06-09 Immunomedics, Inc. Combining radioimmunotherapy and antibody-drug conjugates for improved cancer therapy
US20120028933A1 (en) 2010-07-28 2012-02-02 Baust John M Cell Culture Media Supplement and Method of Molecular Stress Control
JP5665065B2 (ja) 2011-04-28 2015-02-04 国立大学法人大阪大学 リソソーム病治療用医薬組成物
WO2012151199A1 (en) 2011-05-02 2012-11-08 Immunomedics, Inc. Ultrafiltration concentration of allotype selected antibodies for small-volume administration
CN103031277B (zh) * 2011-09-29 2015-07-15 重庆大学 力生长因子在制备无血清培养耐受型哺乳动物工程细胞中的应用
AU2013302696B9 (en) 2012-08-14 2018-08-09 Ibc Pharmaceuticals, Inc. T-cell redirecting bispecific antibodies for treatment of disease
WO2014127200A1 (en) * 2013-02-15 2014-08-21 Immunomedics, Inc. Chimeric and humanized anti-histone antibodies
JP6683598B2 (ja) 2013-03-15 2020-04-22 マックスサイト インコーポレーティッド 安定なトランスフェクトされた細胞を生成するための方法および組成物
US11390663B2 (en) 2013-10-11 2022-07-19 Regeneron Pharmaceuticals, Inc. Metabolically optimized cell culture
PL3055409T3 (pl) * 2013-10-11 2018-10-31 Regeneron Pharmaceuticals, Inc. Metabolicznie zoptymalizowana hodowla komórkowa
ES2978993T3 (es) 2014-02-21 2024-09-23 Ibc Pharmaceuticals Inc Terapia de enfermedades mediante la inducción de la respuesta inmunitaria a las células que expresan Trop-2
CN106029098A (zh) 2014-02-25 2016-10-12 免疫医疗公司 人源化rfb4抗cd22抗体
WO2015200260A1 (en) 2014-06-24 2015-12-30 Immunomedics, Inc. Anti-histone therapy for vascular necrosis in severe glomerulonephritis
CA2961774C (en) 2014-10-07 2023-05-23 Immunomedics, Inc. Neoadjuvant use of antibody-drug conjugates
ES2926467T3 (es) 2015-04-13 2022-10-26 Maxcyte Inc Métodos y composiciones para la modificación del ADN genómico
AU2016252771B2 (en) 2015-04-22 2021-12-16 Immunomedics, Inc. Isolation, detection, diagnosis and/or characterization of circulating Trop-2-positive cancer cells
EP3316885B1 (en) 2015-07-01 2021-06-23 Immunomedics, Inc. Antibody-sn-38 immunoconjugates with a cl2a linker
US10745663B2 (en) * 2015-07-17 2020-08-18 Ares Trading S.A. Methods for modulating production profiles of recombinant proteins
TWI784063B (zh) * 2017-12-27 2022-11-21 財團法人生物技術開發中心 具有增進蛋白質表現功效的宿主細胞及其用途
SG11202013191TA (en) * 2018-07-13 2021-01-28 Lonza Ag Methods for improving production of biological products by reducing the level of endogenous protein
CN111349615B (zh) * 2018-12-24 2024-08-13 上海细胞治疗集团股份有限公司 制备过表达外源基因的细胞的方法
JPWO2022239720A1 (OSRAM) 2021-05-10 2022-11-17
EP4455274A4 (en) * 2021-11-26 2025-12-31 Iucf Hyu ESTABLISHMENT OF AN ERIETHROID PRECURSOR CELL LINE CAPABLE OF CONDITIONAL MATURATION USING GENE OVEREXPRESSION

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0471484A (ja) * 1990-07-11 1992-03-06 Teijin Ltd 低凝集性細胞及びその培養方法
US5550019A (en) 1993-05-26 1996-08-27 La Jolla Cancer Research Foundation Methods of identifying compounds which alter apoptosis
US6492169B1 (en) 1999-05-18 2002-12-10 Crucell Holland, B.V. Complementing cell lines
ATE474052T1 (de) * 1999-09-27 2010-07-15 Genentech Inc Verfahren zur herstellung von rekombinanten proteinen mittels inhibitoren von apoptose
AU2001294520A1 (en) 2000-08-21 2002-03-04 Clonex Development, Inc. Methods and compositions for increasing protein yield from a cell culture
AU2002315534B2 (en) 2001-07-10 2008-05-22 Biogen Idec Inc. Inhibition of apoptosis process and improvement of cell performance
WO2003040374A1 (en) 2001-11-02 2003-05-15 Centocor, Inc. METHODS AND COMPOSITIONS FOR ENHANCED PROTEIN EXPRESSION AND/OR GROWTH OF CULTURED CELLS USING CO-TRANSCRIPTION OF A Bcl2 ENCODING NUCLEIC ACID
US6964199B2 (en) 2001-11-02 2005-11-15 Cantocor, Inc. Methods and compositions for enhanced protein expression and/or growth of cultured cells using co-transcription of a Bcl2 encoding nucleic acid
CA2470026A1 (en) * 2001-12-14 2003-06-26 Centocor, Inc. Clonal myeloma cell lines useful for manufacturing proteins in chemically defined media
EP1348758A1 (en) 2002-03-28 2003-10-01 Boehringer Ingelheim Pharma GmbH & Co.KG Host cells having improved cell survival properties and methods to generate such cells
US20030219871A1 (en) 2002-03-28 2003-11-27 Boehringer Ingelheim Pharma Gmbh & Co. Kg Host cells having improved cell survival properties and methods to generate such cells
JP2006503555A (ja) * 2002-06-26 2006-02-02 バイオジェン・アイデック・エムエイ・インコーポレイテッド タンパク質産生方法および使用するための改変細胞
JPWO2005035740A1 (ja) * 2003-10-09 2006-12-21 協和醗酵工業株式会社 無血清馴化したゲノム改変細胞
US7531327B2 (en) 2004-07-23 2009-05-12 Immunomedics, Inc. Methods and compositions for increasing longevity and protein yield from a cell culture
US7537930B2 (en) 2004-07-23 2009-05-26 Immunomedics, Inc. Mammalian cell lines for increasing longevity and protein yield from a cell culture
CN1287862C (zh) * 2004-09-29 2006-12-06 中国人民解放军第四军医大学 MG7－Ag模拟表位构建胃癌特异性多表位基因疫苗的方法
US20070092947A1 (en) 2005-10-20 2007-04-26 Immunomedics, Inc. Methods and compositions for increasing longevity and protein yield from a cell culture

Also Published As

Publication number Publication date
US20060110793A1 (en) 2006-05-25
AU2006276182B2 (en) 2012-02-16
WO2007015848A3 (en) 2007-10-04
CA2616799A1 (en) 2007-02-08
US7531327B2 (en) 2009-05-12
WO2007015848A9 (en) 2007-04-05
EP1910515A2 (en) 2008-04-16
AU2006276182A1 (en) 2007-02-08
JP2013172722A (ja) 2013-09-05
WO2007015848B1 (en) 2007-11-15
CA2616799C (en) 2015-11-24
JP2009502167A (ja) 2009-01-29
KR20130027579A (ko) 2013-03-15
EP1910515B1 (en) 2019-02-27
EP1910515A4 (en) 2009-03-11
CN101273121B (zh) 2012-07-04
KR20080073282A (ko) 2008-08-08
WO2007015848A2 (en) 2007-02-08
CN101273121A (zh) 2008-09-24
KR101518062B1 (ko) 2015-05-28

Similar Documents

Publication Publication Date Title
JP5301990B2 (ja) 細胞の培養寿命の延長および培養細胞からのタンパク質収量を増加させるための改良された方法および組成物
US8569054B2 (en) Mammalian cell lines for increasing longevity and protein yield from a cell culture
US7608425B2 (en) Methods for protein expression in mammalian cells in serum-free medium
JP2022033734A (ja) グルタミンシンセターゼ遺伝子内相補ベクターを用いた高レベルのヘテロマータンパク質発現細胞の直接選択
JP2012254084A (ja) 細胞培養物の寿命および由来するタンパク質の収率を増加させるための方法および組成物
JP2013165728A (ja) 抗老化性の化合物を使用する蛋白の生成方法
TW200307044A (en) Host cells having improved cell survival properties and methods to generate such cells
US20070092947A1 (en) Methods and compositions for increasing longevity and protein yield from a cell culture
AU2005333513B2 (en) Methods and compositions for increasing longevity and protein yield from a cell culture

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090707

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20090707

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20111209

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120309

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120316

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120409

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20121214

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20130215

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130412

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20130419

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130521

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130524

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20130618

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20130620

R150 Certificate of patent or registration of utility model

Ref document number: 5301990

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250